A Bayesian population PK-PD model of ispinesib-induced myelosuppression

Clinical Pharmacology and Therapeutics

Volumn 81, Issue 1, 2007, Pages 88-94

  Kathman, S J ^a   Williams, D H ^a   Hodge, J P ^a   Dar, M ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISPINESIB;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BAYES THEOREM; BONE MARROW SUPPRESSION; CANCER PATIENT; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG INDUCED DISEASE; DRUG INFORMATION; FEMALE; HUMAN; MALE; MITOSIS SPINDLE; MONTE CARLO METHOD; MULTIPLE CYCLE TREATMENT; NEUTROPHIL COUNT; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BAYES THEOREM; BENZAMIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LEUKOCYTE COUNT; MALE; MARKOV CHAINS; MIDDLE AGED; MODELS, BIOLOGICAL; MONTE CARLO METHOD; NEUTROPENIA; QUINAZOLINES;

EID: 33846030767     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100021     Document Type: Article

References (16)

1. Friberg, L., Henningsson, A., Maas, H., Nguyen, L. & Karlsson, M. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J. Clin. Oncol. 20, 4713-4721 (2002).
2. Friberg, L. & Karlsson, M. Mechanistic models for myelosuppression. Invest. New Drugs 21, 183-194 (2003).
3. Sheiner, L. & Wakefield, J. Population modelling in drug development. Stat. Methods Med. Res. 8, 183-193 (1999).
4. Robert, C. & Casella, G. Monte Carlo Statistical Methods, (Springer, New York, 2004).
5. Duffull, S., Kirkpatrick, C., Green, B. & Holford, N. Analysis of populations pharmacokinetic data using NONMEM and WinBugs. J. Biopharm. Stat. 15, 53-73 (2005).
6. Congdon, P. Applied Bayesian Modelling, (John Wiley and Sons Ltd, UK, 2003).
7. Spiegelhalter, D., Best, N. & Carlin, B. Bayesian measures of model complexity and fit. J. Roy. Stat. Soc. Ser. B 64, 583-639 (2002).
8. Friberg, L., Dansirikul, C. & Dufful, S. Simultaneous fit of competing models as a model discrimination tool in a fully Bayesian approach. In Population Approach Group Europe, (Uppsala, Sweden, 2004), Page 13 Abstr 493 [www.page-meeting.org/?abstract=493].
9. Spiegelhalter, D., Thomas, A., Best, N. & Gilks, W. BUGS: Bayesian Inference using Gibbs Sampling, Version 1.4.1. (MRC Biostatistics Unit, Cambridge, 2003).
10. Lunn, D., Best, N., Thomas, A., Wakefield, J. & Spiegelhalter, D. Bayesian analysis of population PK/PD models: general concepts and software. J. Pharmacokinet. Pharmacodyn. 29, 271-307 (2002).
11. Gelman, A., Carlin, J.B., Stern, H.S. & Rubin, D.B. Bayesian Data Analysis, (Chapman & Hall, London, 2003).
12. Karlsson, M. et al. Pharmacokinetic/pharmacodynamic modelling in oncological drug development. Basic Clin. Pharmacol. Toxicol. 96, 206-211 (2005).
13. Latz, J., Karlsson, M., Rusthoven, J., Ghosh, A. & Johnson, R. A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy. Cancer Chemother. Pharmacol. 57, 412-426 (2006).
14. Sandstrom, M., Lindman, H., Nygren, P., Lidbrink, E., Bergh, J. & Karlsson, M.O. Model describing the relationship between pharmacokinetics and hematologic toxicity of the Epirubicin-Docetaxel regimen in breast cancer patients. J. Clin. Oncol. 23, 413-421 (2005).
15. Troconiz, I. et al. Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intra-venous diflomotecan in patients with advanced malignant tumours. Cancer Chemother. Pharmacol. 57, 727-735 (2006).
16. Sandstrom, M., Lindman, H., Nygren, P., Johansson, M., Bergh, J. & Karlsson, M.O. Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients. Cancer Chemother. Pharmacol. 58, 143-156 (2006).